US Pharmaceutical CMO Market Share

Statistics for the 2023 & 2024 US Pharmaceutical CMO market share, created by Mordor Intelligence™ Industry Reports. US Pharmaceutical CMO share report includes a market forecast to 2029 and historical overview. Get a sample of this industry share analysis as a free report PDF download.

Market Share of US Pharmaceutical CMO Industry

The US pharmaceutical contract manufacturing organization (CMO) market is highly competitive and fragmented, which consists of several major players, and with new development facilities and application of new drugs, the market caters to an intense rivalry. Key players are Catalent Inc. and Recipharm AB. Recent developments in the market are -

  • February 2020 - Alchem Laboratories Corporation announced an expansion of its screening and clinical trial manufacturing capabilities. The expansion was made through construction of Building 3, a 12,000 square foot multi-use facility dedicated to high-throughput screening, biologic and drug product manufacturing clean-room areas, and analytical support.
  • December 2019 - Thermo Fisher Scientific Inc. introduced its new USD 90 million viral vector CDMO site in Lexington, Massachusetts. The 50,000-square-foot facility will support the development, testing, and manufacture of viral vectors, which are critical to advancing new life-saving gene and cell therapies.

US Pharmaceutical Contract Manufacturing Organization Market Leaders

  1. Catalent Inc.​

  2. Recipharm AB​

  3. Jubilant Life Sciences Ltd​

  4. Thermo Fisher Scientific Inc. (Patheon Inc.)

  5. Boehringer Ingelheim Group​

*Disclaimer: Major Players sorted in no particular order

"Catalent Inc.​ Recipharm AB​ Jubilant Life Sciences Ltd​ Thermo Fisher Scientific Inc. (Patheon Inc.) Boehringer Ingelheim Group​"

US Pharmaceutical Contract Manufacturing Organization Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)